Compare VTOL & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | EOLS |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 444.0M |
| IPO Year | N/A | 2018 |
| Metric | VTOL | EOLS |
|---|---|---|
| Price | $36.65 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | 148.5K | ★ 843.1K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 148.42 | N/A |
| EPS | ★ 4.78 | N/A |
| Revenue | ★ $1,466,774,000.00 | $285,823,000.00 |
| Revenue This Year | $7.31 | $14.24 |
| Revenue Next Year | $9.55 | $21.77 |
| P/E Ratio | $7.67 | ★ N/A |
| Revenue Growth | 2.95 | ★ 15.10 |
| 52 Week Low | $25.11 | $5.71 |
| 52 Week High | $42.89 | $17.12 |
| Indicator | VTOL | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 43.24 |
| Support Level | $36.01 | $6.57 |
| Resistance Level | $37.00 | $6.80 |
| Average True Range (ATR) | 0.83 | 0.22 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 43.97 | 12.34 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, India, Ireland, the Kingdom of Saudi Arabia, Mexico, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the UK, and the U.S. offshore energy customers use services to transport personnel to, from and between offshore energy installations.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.